Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
about
Mechanism of action of lenalidomide in hematological malignanciesMechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaPomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroThalidomide analogues as anticancer drugsA Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo NodularisPomalidomide for the treatment of multiple myelomaImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Emerging drugs for chronic lymphocytic leukaemia.Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissuePhase I study of oral lenalidomide in patients with refractory metastatic cancerImmunomodulation by thalidomide and thalidomide analoguesPhase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Thalidomide-a notorious sedative to a wonder anticancer drug.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaImmunotherapeutic and antitumour potential of thalidomide analogues.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsThalidomide and lenalidomide: Mechanism-based potential drug combinations.Lenalidomide in the treatment of multiple myeloma: a review.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Future prospects of anticytokine therapy in chronic heart failure.Multiple myeloma: an update of developments in targeted therapy.Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.Properties of thalidomide and its analogues: implications for anticancer therapy.Immunomodulatory drugs.Pharmacokinetics and tissue disposition of lenalidomide in mice.Current therapeutic uses of lenalidomide in multiple myeloma.Lenalidomide: an immunomodulatory drug.Pharmacotherapy of multiple myeloma.Lenalidomide in multiple myeloma.The emerging role of lenalidomide in the management of lymphoid malignancies
P2860
Q21198872-0EE076FF-2620-4F84-80A6-DDF15FB20C4EQ24605861-A08F8AC8-9497-4840-8A1F-E11676F27BBBQ24634078-55A533E2-3762-46DE-8459-60964A561E93Q24670383-C475E150-76D6-489C-BB1F-861E73075C4EQ26747036-0A139534-6A36-4EB8-9F54-3FF26015FFEDQ26859133-5708E675-CE11-4FD4-AB2C-3B6698A550ACQ27001318-E45EACEB-D8D1-4B8D-A0AD-E622E726F98BQ30235355-C1033D83-8668-49B1-A174-DD8E80600407Q30353154-879DADA1-D704-445D-9E6D-24107BD7BD06Q33322921-CD4614BE-E0F0-4E89-B27D-6219BBE36022Q33403183-5E48A7DD-90D6-4197-B04D-F34F0D83973BQ33429608-4F48ED9A-88D7-4E3F-ABD0-DBB2AA92CA26Q33459422-BD84B287-C6AA-471C-84FC-AACCAE378C22Q33600521-89862EDA-5F31-4229-B564-9B8F95035B4AQ33782386-7CC95255-7953-443D-8099-98B6E6E272C8Q33813750-90C36E57-FD0E-4A38-AA9F-4A1518135580Q33956871-904F6621-75F3-404F-8D38-E874850D1B6BQ33960866-BB703E99-695F-41EB-8359-A267E05C31A0Q34329242-D87D08C6-D348-42E4-B24D-DE7F6872B756Q34369823-FA0FE20D-8A5B-4372-ACAD-6DCE2654B8DDQ34451909-3FA9AF05-C4CC-48C4-9B03-C844F66D1291Q34454532-2B619D69-AEE7-4293-AC67-BCC978B63874Q34661167-B8B67F6E-372E-4165-9A92-168E6E99E42CQ34775475-286D3ABA-60A9-41F4-93B6-BEE052EC733CQ34775515-CE760410-C5CD-45DA-96F8-AE799E8DA96BQ35175287-7C853FA5-938D-41C5-A6E8-F7E8753ECE13Q35182727-65D7F492-4F8C-4F64-B420-7E98AF686E44Q35609611-E292F54F-5293-4741-A9F5-E532148CB53EQ35844148-8AB10CB4-8C55-406E-A880-7A9473DCEEE2Q36087238-F36257E6-2067-4C5D-8659-F94AEB49B3E3Q36118436-0BED0D14-1F29-4BA4-A85F-643BE039A251Q36132803-939436AA-99A5-4660-B38C-8DD5566441E7Q36250757-1A9B4F95-842B-423D-AEC4-C9FFE4232A05Q36321396-FBFD83DF-4C14-4432-9A96-884712CF02A6Q36331493-D142CACB-11EC-4144-A91D-188D6186C814Q36376450-CEDD4DFA-C34C-4019-9CE6-925E49F76BFBQ36429554-834C698F-A7E4-4CF2-B771-6C6990A362C3Q36429735-CAC9D73F-36A6-47FF-A25C-DC7B01417A18Q36573818-C690EA0B-BE57-47A5-9A3C-5FA9CB7D87FAQ36612543-FB49E346-C82E-489B-95D6-B7A74A7009EC
P2860
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@ast
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@en
type
label
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@ast
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@en
prefLabel
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@ast
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@en
P2093
P1476
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
@en
P2093
Patterson RT
Stirling DI
P304
P356
10.1016/S0960-894X(99)00250-4
P407
P577
1999-06-01T00:00:00Z